Savient Pharmaceuticals
| Industry | Pharmaceuticals |
|---|---|
| Defunct | 2013 |
| Headquarters | , United States |
| Products | Pegloticase, oxandrolone |
| Website | http://www.savientpharma.com/ |
Savient Pharmaceuticals was a New Jersey–based biopharmaceutical company. Its lead product, pegloticase, was a biologic drug for treatment resistant chronic gout, which it marketed beginning in 2011.[1] It also marketed oxandrolone beginning in 1995.[2]
History
[edit]Savient was incorporated in 1980 as Bio-Technology General Corp and changed its name in 2003.[3]
Savient later focused on commercializing pegloticase in the United States and completing the development and seeking regulatory approval in the European Union.[citation needed] The company also sold branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. John H. Johnson was CEO from February 2011 until February 2012, formerly employed by Imclone Systems.[4]
Savient declared bankruptcy in 2013.[5] The drug was selling at $5,390 per vial—around $30,000 for a three-month course of treatment—at the time Savient went under.[6]
Savient was then bought by Crealta.[6] In 2015, Crealta was able to sell the asset to Horizon Pharma for $510 million that year.[6]
References
[edit]- ^ Monica Holmberg, PharmD (2011-04-18). "Savient Pharmaceuticals, Inc's Krystexxa". Pharmacy Times. April 2011 Allergy & Asthma. 77 (4).
- ^ "UPDATE 1-Savient says court lifts sale ban on oxandrolone". Reuters. 2007-01-20. Retrieved 2022-05-12.
- ^ Press release: Bio-Technology General Corp. Announces Company Name Change to Savient Pharmaceuticals, Inc. June 17, 2003
- ^ "Ex-CEO of East Brunswick's Savient Pharmaceuticals headed to Dendreon". nj. 2012-02-01. Retrieved 2020-05-12.
- ^ "Savient Pharmaceuticals files for Chapter 11 bankruptcy". Reuters. 2013-10-15. Retrieved 2022-04-21.
- ^ a b c Engel, Jeff (14 December 2015). "Crealta Spins Struggling Arthritis Drug Into $510M Horizon Payday | Xconomy". Xconomy.
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |